Antibody-Drug Conjugates: The 2026 Cancer Treatment Revolution
By Dr. Sarah Mitchell, Certified Respiratory Therapist & Wellness Editor · Published 2026-08-14 · 8 min read
ADCs like Enhertu and Trodelvy are rewriting metastatic breast, lung, and bladder cancer survival curves. A 2026 clinician-friendly overview.
Chemo With a GPS
Antibody-drug conjugates fuse a tumor-targeting monoclonal antibody to a cytotoxic payload, sparing healthy tissue and delivering doses 100x higher inside the cancer cell.
Practice-Changing Data
- Enhertu (T-DXd) — doubled PFS in HER2-low breast cancer (DESTINY-Breast06).
- Trodelvy — extends OS in triple-negative and HR+ breast cancer.
- Padcev + Keytruda — new first-line standard for metastatic urothelial cancer.
On the Horizon
Datopotamab-DXd for NSCLC, Ifinatamab-DXd for small cell lung cancer, and bispecific ADCs entering phase 1.
---
Round Out Your Home Health Setup
Pair the latest wellness protocols with clinical-grade monitoring. Browse portable oxygen concentrators, CPAP machines, and respiratory accessories — or call our respiratory therapists at (877) 699-4365 for a free consult.
← Back to all articles